Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Net Margin (2024 - 2025)

Historic Net Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to 212.1%.

  • Monte Rosa Therapeutics' Net Margin rose 467900.0% to 212.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.52%, marking a year-over-year increase of 8088900.0%. This contributed to the annual value of 96.18% for FY2024, which is N/A changed from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Net Margin of 212.1% as of Q3 2025, which was up 467900.0% from 53.01% recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Net Margin registered a high of 55.2% during Q1 2025, and its lowest value of 3006.11% during Q1 2024.